Expression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: a histopathological study

Abstract

Our objective was to examine the expression rates of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium. A total of 94 endometrial frozen sections (carcinoma 48, hyperplasia 21, normal tissue 25) were examined immunohistochemically in terms of the expression rates of p53, Bcl-2 and Bax. All of the specimens in the non-malignant groups were positive for Bax, whereas this rate was 85.4% in the group with malignant specimens (p = .03). Conversely, p53 was expressed only in the cancerous group (77.1%, p < .001). The Bcl-2 expression rate was 54.2% in the cancer group, 76.2% in the group with hyperplasia and 60% in the group containing normal tissue (p = .23). Comparing to the non-malignant specimens, the mean Bcl-2/Bax were significantly higher in the malignant group. In conclusion, Bax under-expression, p53 over-expression and a high Bcl-2 to Bax ratio might be associated with endometrial carcinoma. Bcl-2, however, plays no significant role in this regard. Impact statement What is already known on this subject? The p53, Bcl-2 and Bax are the three major genes that regulate apoptosis. Some studies have suggested that these genes may play a role in the pathogenesis of endometrial carcinoma. The available reports, however, are old and inconclusive. What do the results of this study add? Comparing immunohistochemically obtained p53, the Bcl-2 and Bax expression rates between normal endometrial tissue, endometrial specimens with endometrial hyperplasia and specimens with carcinoma showed that Bax under-expression, p53 over-expression and a high Bcl-2 to Bax ratio were associated with malignancy. Using an up-to-date technique to examine the three major regulators of apoptosis at the same time, in a rather large sample size of both normal and abnormal endometrial tissue specimens simultaneously, are the major advantages of the present work. What are the implications of these findings for clinical practice and/or further research? According to our findings, the status of p53, Bcl-2 and Bax expression in the endometrial tissue can be used for risk stratification of endometrial carcinoma for both screening and preventive purposes.

SNHG1 promotes proliferation, migration and invasion of bladder cancer cells via the PI3K/AKT signaling pathway

“…Bcl-2 is a potent inhibitor of apoptosis and increases proliferation ( 27 ). Furthermore, the Bcl-2/Bax ratio is the critical determinant for the induction or inhibition of apoptosis ( 28 ). PCNA is present in nuclei throughout the cell cycle and is synthesized in the late G 1 and S phases ( 29 ).…”

Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer

“…To further verify the inhibitory effect of siASF1B on apoptosis, factors associated with apoptosis were investigated. Bax and p53 are pro-apoptotic genes, and Bcl-2 is an anti-apoptotic gene ( 41 , 42 ). Additionally, studies demonstrated that the activity of caspase-3 is strengthened during the process of cell apoptosis ( 43 - 45 ).…”

Escins Isolated from Aesculus chinensis Bge. Promote the Autophagic Degradation of Mutant Huntingtin and Inhibit its Induced Apoptosis in HT22 cells

“…Accumulating evidences indicate that mHtt induces cytotoxicity via enhancing oxidative stress and results in the activation of apoptotic signaling pathway (Nellemann et al, 2000;Pandey and Rajamma, 2018). The Bcl-2 family, which includes Bax and Bcl-2, plays a central role in the regulation of the mitochondria-mediated apoptosis (Wu et al, 2016;Mirakhor et al, 2018). Caspase 3 and caspase 9, downstream of the apoptotic signaling pathway, are proteolytic enzymes that function as key proteins to promote apoptosis (Wu et al, 2012a;Yao et al, 2017).…”